RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help doctors learn how pemetrexed disodium works in the body and identify biomarkers related to cancer. PURPOSE: This clinical trial is studying the side effects and how well pemetrexed disodium works in treating patients with leptomeningeal metastases.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Correlation of cerebrospinal fluid levels with plasma levels of different doses of pemetrexed disodium
Timeframe: Every 6 weeks for assessment while on study.
To determine whether there is any anti-tumor activity against LM with Pemetrexed.
Timeframe: Every six weeks.
To determine the safety of Pemetrexed in patients with LM.
Timeframe: After every 2 doses approximately 6 weeks
To assess the role of serum biomarkers in patients with LM.
Timeframe: Prior to dose one